Trial Profile
A Phase I Study of Cisplatin, Paclitaxel, and RAD001 in Patients with Metastatic Breast Cancer (SPORE).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Everolimus (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 19 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Oct 2010 Planned end date changed from 1 Mar 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 31 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.